PDSB
PDS Biotechnology Corporation
NASDAQ · Healthcare · Biotechnology · US
$0.22
+0.27%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
Market Cap
$12.35M
MomentumView details →
1D Return
+0.27%
YTD Return
−71.33%
RSI (14)
24.4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
Market Cap
$12.35M
RSI (14)
24.4
MomentumView details →
1D Return
+0.27%
YTD Return
−71.33%
SummaryUpdated Jun 1, 2026
PDS Biotechnology Corporation (NASDAQ:PDSB) is a clinical-stage biopharmaceutical company founded in 2005 and headquartered in Florham Park, New Jersey. The company focuses on developing multifunctional cancer immunotherapies using its proprietary Versamune platform technology. Since going public in 2015, PDS has advanced multiple product candidates through clinical trials, with its lead program targeting HPV-positive cancers currently in Phase 3 development. The company operates as a pure-play biotechnology firm with no current revenue, relying on clinical trial advancement and potential partnerships to drive value creation.
Similar companies
Latest newsMore news →
PDS Biotechnology Corp terminated Stephan Toutain as Chief Operating Officer, effective August 21, 2026, with severance of twelve months' base salary and COBRA contributions.11d agoLars Boesgaard resigned as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of PDS Biotechnology Corp, effective September 12, 2026, and Janetta Trochimiuk was appointed interim Principal Accounting Officer effective the same date.17d agoPDS Biotechnology Corp reported a net loss of $9.8 million for Q2 2026, with a net loss per diluted share of $0.18, compared to a net loss of $9.4 million ($0.21 per share) in Q2 2025.23d ago